iVexSol Revenue and Competitors
Estimated Revenue & Valuation
- iVexSol's estimated annual revenue is currently $2.2M per year.
- iVexSol's estimated revenue per employee is $77,500
- iVexSol's total funding is $15.3M.
Employee Data
- iVexSol has 29 Employees.
- iVexSol grew their employee count by -12% last year.
iVexSol's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | SVP Operations | Reveal Email/Phone |
3 | Head Quality Assurance | Reveal Email/Phone |
4 | SVP, BD&L | Reveal Email/Phone |
5 | Head Marketing and Communications | Reveal Email/Phone |
6 | Director Business Development | Reveal Email/Phone |
7 | Sr. Director Quality | Reveal Email/Phone |
8 | Sr. Director Facilities & Engineering | Reveal Email/Phone |
9 | Executive Director | Reveal Email/Phone |
10 | Finance Manager | Reveal Email/Phone |
iVexSol Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is iVexSol?
As Lentiviral vectors have transformed medicine with their safety and efficacy, they have created a demand for production that far exceeds current capacity. Traditional manufacturing systems have seen long wait times and critical raw material shortages cause delays in development and deployment of these life-altering therapies. Our Intelligent Vector Solutions(TM) can be used to manufacture ANY LENTI, ANY SCALE(TM) to provide our clients an END TO END solution, speeding their development and securing their supply chain. iVexSol, where technology meets capacity.
keywords:N/A$15.3M
Total Funding
29
Number of Employees
$2.2M
Revenue (est)
-12%
Employee Growth %
N/A
Valuation
N/A
Accelerator
iVexSol News
WORCESTER, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- iVexSol, a rapidly growing lentiviral vector (LVV) manufacturing company, today announced the closure of a $13.0M Series A funding round. A total of $15.2M has been raised to date from current investors Casdin Capital, LLC , and BioLife Solutio ...
iVexSol, a Boston, MA-based viral vector manufacturing company, raised $2.0m in new convertible debt funding. The round was led by Casdin Capital and BioLife Solutions (NASDAQ:BLFS). The company intends to use the funds to advance the development of its solutions. Led by CEO Dr. Rodney Rietze ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.3M | 29 | 7% | N/A |
#2 | $4.3M | 30 | 88% | N/A |
#3 | $5.7M | 30 | -6% | N/A |
#4 | $8M | 31 | 0% | N/A |
#5 | $6.7M | 31 | 7% | N/A |